OR WAIT null SECS
October 02, 2025
Article
Read about hepatic FDA news, the voluntary withdrawal of obeticholic acid for PBC, new trial data for a potential AATD drug, and more.
September 03, 2025
WVE-006 drove production of M-AAT, which is protective of lung function, and reduced mutant Z-AAT, a cause of liver disease.
May 21, 2025
Video
Stoller describes the potential of a novel AI model to help address AATD underrecognition, citing findings from his research on its performance in a Cleveland Clinic cohort.
April 17, 2025
Meta-analysis results showed patients with ZZ AATD had a greater risk of liver disease and liver cancer than patients in comparator cohorts.
December 17, 2024
Clark reviews open-label extension data from the phase 2b SEQUOIA study of fazirsiran for AATD liver disease.
November 27, 2024
Fromme describes the importance of risk stratification in AATD and explains the potential utility of noninvasive fibrosis measures for predicting outcomes.
November 26, 2024
Strnad reviews findings from a proteomic analysis about AATD-associated liver disease and how they may aid future disease monitoring and drug development.
November 18, 2024
Teckman explains the value of a new predictive algorithm model for determining future risk of portal hypertension, cirrhosis, and liver transplant in AATD.
October 16, 2024
Proof-of-mechanism data from the phase 1b/2a study of WVE-006 represent the first-ever clinical demonstration of RNA editing in humans.
September 25, 2024
Findings from the prospective cohort study suggest the value of serum Z polymer levels as a non-invasive disease-specific biomarker in patients with homozygous ZZ AATD liver disease.
